Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/09/2021 06/10/2021 06/11/2021 06/14/2021 06/15/2021 Date
1.08(c) 1.02(c) 1(c) 1.02(c) 0.9658(c) Last
46 412 828 7 324 881 10 321 184 4 821 262 3 689 468 Volume
+6.93% -5.56% -1.96% +2.00% -5.31% Change
More quotes
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,68x
Yield 2021 -
Sales 2022 21,2 M - -
Net income 2022 -18,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,15x
Yield 2022 -
Capitalization 144 M 144 M -
Capi. / Sales 2021 6,54x
Capi. / Sales 2022 6,78x
Nbr of Employees 130
Free-Float 99,1%
More Financials
Company
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled... 
Sector
Pharmaceuticals
Calendar
08/16Earnings Release
More about the company
Ratings of Adamis Pharmaceuticals Corporation
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ADAMIS PHARMACEUTICALS CORPORATION
06/14ADAMIS PHARMACEUTICALS  : Files Definitive Proxy Statement and Sends Letter to S..
BU
06/14ADAMIS PHARMACEUTICALS  : Provides Update on Clinical Trial Start-Up Progress fo..
AQ
06/11ADAMIS PHARMACEUTICALS  : Starts Preparation for Clinical Trial on COVID-19 Drug..
MT
06/11Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the ..
GL
06/09ADAMIS PHARMACEUTICALS  : FDA Accepts Adamis' Resubmitted New Drug Application f..
MT
06/09Adamis Provides Update on ZIMHI™
GL
06/07ADAMIS PHARMACEUTICALS  : Says NIH Study Found Its Tempol Drug Candidate to be P..
MT
06/07ADAMIS PHARMACEUTICALS  : Highlights National Institute of Health Study Identify..
AQ
06/01ADAMIS PHARMACEUTICALS  : Announces Receipt of Deficiency Letter from Nasdaq (Fo..
PU
06/01ADAMIS PHARMACEUTICALS CORP  : Notice of Delisting or Failure to Satisfy a Conti..
AQ
06/01Adamis Pharmaceuticals Provides Business Update
GL
06/01ADAMIS PHARMACEUTICALS  : Gets Non-Compliance Warning From Nasdaq on Late Form 1..
MT
05/31ADAMIS PHARMACEUTICALS  : Announces Receipt of Deficiency Letter from NASDAQ
AQ
05/28Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
GL
05/27ADAMIS PHARMACEUTICALS CORP  : Change in Directors or Principal Officers, Financ..
AQ
More news
News in other languages on ADAMIS PHARMACEUTICALS CORPORATION
2019Novartis macht Adamis Notfallallergie-Shots über Apotheken verfügbar
2017Feu vert de la FDA au traitement d'Adamis concurrent de l'EpiPen
2016Mylan lance un générique deux fois moins cher de son EpiPen
2015Les valeurs à suivre sur les marchés américains
More news
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price
Last Close Price 0,97 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
NameTitle
Dennis J. Carlo President, Chief Executive Officer & Director
Robert O. Hopkins Chief Financial Officer & Secretary
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capitalization (M$)
ADAMIS PHARMACEUTICALS CORPORATION99.09%144
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.8.10%204 582